iBio’s Chief Legal Officer Buys 25,000 Shares Amid Stock’s 56% YTD Decline, Signaling Executive Confidence

Insider Buying Surge Amid a Slumping Stock Banjak Marc, iBio’s Chief Legal Officer, added 12,500 shares on March 26, 2026, at $1.64, followed by a second purchase of 1,434 shares at $1.76. The deal brought his total holdings to 25,000 shares, a 7 % increase from the 23,566 shares held after the earlier transaction on March 26. Although the price move was negligible (0.01 %) and the overall market sentiment for iBio remains neutral, the buzz surrounding the filing spiked to 11.94 %—well above the typical 100 % baseline—suggesting that investors are paying closer attention to insider activity as the stock continues its steep decline.

What This Means for Investors iBio’s share price has dropped 56 % year‑to‑date and 38 % in March alone, while its market cap sits at just $72.5 million. In such a context, insider buying can be a double‑edged sword: on one hand, it signals confidence from management in the company’s long‑term prospects; on the other, it can be a strategic move to shore up a diluted shareholder base. The fact that Banjak’s purchases follow a pattern of exercising stock options (146,000 shares acquired on January 28 and 55,000 on October 20) indicates a willingness to invest heavily in the company’s equity even when the price is low. For investors, this may justify a cautious “buy‑the‑dip” stance, especially if the company is on track to deliver its next product launch or secure a pivotal partnership in plant‑made therapeutics.

A Profile of Banjak Marc Marc has consistently used his insider status to build a sizable equity stake. His earliest disclosed purchase was a 55,000‑share option grant in October 2025, followed by a larger 146,000‑share grant in January 2026—both acquired at zero cost. The recent two‑day buying spree in March further cements a pattern of active participation: each transaction is executed at market price, indicating confidence rather than a speculative play. Compared to peers—such as CFO Duran Felipe, who has also bought options but at no cost—the difference lies in the immediacy of market purchases. Marc’s buying behavior suggests a long‑term commitment to iBio’s mission and a belief that the current price undervalues the company’s future potential.

Looking Ahead With the stock hovering around $1.74 and a 52‑week high of $4.23, iBio still has upside space, especially if its pipeline hits critical milestones. Insider activity like Banjak’s may serve as a bellwether for confidence, but investors should also weigh the company’s fundamental risks—negative price‑earnings ratio, steep declines, and a volatile market environment. For those considering a position in iBio, the recent insider purchases could be a signal to monitor, provided that the broader market dynamics and the company’s clinical development trajectory support a rebound.

Bottom Line Insider buying by Banjak Marc is a positive sign of executive confidence amid a challenging market environment. While it does not guarantee a turnaround, it does suggest that the company’s leadership remains invested in its long‑term strategy. Investors should weigh this insider optimism against iBio’s current valuation, recent performance, and the broader health‑care biotechnology landscape before deciding on an entry point.